Alex Clarkson ACA, MCSI
Alex is an experienced corporate financier, investor and co-founder. Having spent his early years in Transaction Services and Due Diligence with PwC, he has since developed a broad range of advisory skills and trusted relationships across capital markets with a range of UK equity investors, private equity firms, high net worth individuals and banks. After PwC, Alex spent three years in Corporate Finance as part of the respected Brewin Dolphin Corporate Advisory and Broking team. Alex has been key to establishing and creating value in numerous companies including Zeus Group and Collagen Solutions.
Michael Parkinson FCA
Michael has a broad range of experience including 13 years as a respected analyst and corporate broker at Brewin where he played a pivotal role in a number of successful IPOs and secondary fund raisings. Prior to Brewin, Michael spent several years in Transaction Services and Due Diligence at PwC. Before joining the Bamburgh Capital team, Michael spent 3 years as CFO of private energy support services company, Cenergist Limited. He was ranked No 1 stock picker, twice, in Europe for the Support Services sector by FTSE Starmine.
Paul Cooper ACA FCA CTA
Paul is an experienced private equity executive and former Big 4 partner, he has a wealth of advisory experience in M&A, disposals, restructuring and equity/debt raising. In private equity Paul was previously Chief Operating Officer of Lion Capital and a director at Terra Firma Capital Partners. His other advisory roles have included being a Deals Partner at PwC, UK Head of Transactions Tax at Grant Thornton and an M&A Partner at KPMG. He is currently the CEO of Bute Energy Ltd and a Partner and COO of Grayling Capital LLP.
Murdo is an experienced corporate finance and investor relations professional. As a former Director of UK Investment Banking at Credit Suisse, he has a wealth of transaction and equity market experience. This experience is complemented by senior finance/investor relations roles, including as IR Director of The Sage Group PLC and IR Director and Head of Financial Planning & Analysis at Venator Materials PLC. He started his career with HSBC, joining their corporate finance graduate training programme, after graduating from St. Andrews University.
Ed has a range of experience having started his career as an analyst at GSA Capital Partners LLP, a quantitative hedge fund. Prior to joining Bamburgh Capital he spent 4 years at outsourced investment office Partners Capital LLP, where he worked on private and institutional client portfolios ranging from £5 million to over £1 billion, investing across all asset classes. Ed holds the Investment Management Certificate.
Matt Wynne ACA
Matt is ACA qualified and joined the team from KPMG having spent over 5 years advising a wide variety of listed, private equity backed and owner managed businesses. Matt’s clients generally operated across a wide range of industries with revenue typically between £20m-500m. Matt also holds a BSc in Accounting from Durham University.
Chris Brinsmead CBE
Chris worked in the Pharmaceutical industry for over thirty years, holding executive leadership roles with ICI, Zeneca and Astrazeneca. He is a Non Executive director of several private and listed companies including UDG plc and The Wesleyan Assurance Society. He is Chairman at Proveca Ltd and a Member of Council at Imperial College. He co-founded Bamburgh Capital (renamed from Diagnostic Capital in 2016) with David Evans and Alex Clarkson in 2010. Chris was appointed a CBE in January 2015.
David Evans CA
David is an experienced Chairman and investor. He has a strong track record in taking companies through the IPO process and delivering significant value to shareholders. Most recently achieved successful exits for Sirigen (upto 4x value uplift), BBI (4x) and Scipac (exit achieved within 12 months of joining) as well as creating substantial uplifts in value during his tenure as Chairman for IDS (20x), Optibiotix Health (10x), DxS (10x), Scancell (5x) and Epistem (3x). He has considerable M&A experience including cross-border deals with over 20 transactions completed in the diagnostics/life sciences space. He is currently Chairman of Collagen Solutions plc and Omega Diagnostics plc. Previous roles include CEO of Axis-Shield plc and Chairman of Premaitha Health plc. Having co-founded Bamburgh Capital, David remains a shareholder and consultant.
Stuart Sharp LL.B
Stuart qualified as a solicitor at respected Scottish firm Brodies, WS, after reading Law at Edinburgh University. His exceptional 30 year career in the investment industry began in Scotland with Aberdeen Trust. He then joined Yorkshire-based Rensburg Fund Management (now Franklin Templeton Investments) and was a founding member of its successful funds team. As Investment Director there for over 10 years he was instrumental in growing funds from £30 million to over £1 billion. He has won numerous UK investment industry awards for performance particularly in the Equity Income and UK Smaller Company sectors. Following retirement from fund management in 2012, Stuart founded his own trusted consultancy to provide specialist investment counsel to Family Offices, High Net Worth Individuals and Charitable Foundations. He joined Bamburgh Capital as a consultant in 2017.
© 2019 Bamburgh Capital Limited. All Rights Reserved. Registered in England and Wales No. 07155076. Bamburgh Capital Investor Relations Limited. Registered in England and Wales No. 10144004 . Registered Office: 10th Floor, Chancery Place, 50 Brown Street, Manchester M2 2 JT. Bamburgh Capital Limited is regulated and authorised by the Financial Conduct Authority.